Trial Profile
Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Mitiglinide (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 24 May 2016 New trial record